Runx1 deletion or dominant inhibition reduces Cebpa transcription via conserved promoter and distal enhancer sites to favor monopoiesis over granulopoiesis.
about
The RUNX1 +24 enhancer and P1 promoter identify a unique subpopulation of hematopoietic progenitor cells derived from human pluripotent stem cellsMolecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice.Logical modeling of lymphoid and myeloid cell specification and transdifferentiation.The Cebpa +37-kb enhancer directs transgene expression to myeloid progenitors and to long-term hematopoietic stem cells.Granulopoiesis requires increased C/EBPα compared to monopoiesis, correlated with elevated Cebpa in immature G-CSF receptor versus M-CSF receptor expressing cells.The +37 kb Cebpa Enhancer Is Critical for Cebpa Myeloid Gene Expression and Contains Functional Sites that Bind SCL, GATA2, C/EBPα, PU.1, and Additional Ets Factors.Nfix expression critically modulates early B lymphopoiesis and myelopoiesisIn Vivo Deletion of the Cebpa +37 kb Enhancer Markedly Reduces Cebpa mRNA in Myeloid Progenitors but Not in Non-Hematopoietic Tissues to Impair Granulopoiesis.Runx1 Phosphorylation by Src Increases Trans-activation via Augmented Stability, Reduced Histone Deacetylase (HDAC) Binding, and Increased DNA Affinity, and Activated Runx1 Favors GranulopoiesisThe potential of a single enhancerEVI1 Interferes with Myeloid Maturation via Transcriptional Repression of Cebpa, via Binding to Two Far Downstream Regulatory Elements.CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity.Runx1 deficiency permits granulocyte lineage commitment but impairs subsequent maturation.RUNX1: A microRNA hub in normal and malignant hematopoiesis.Systems approach to phagocyte production and activation: neutrophils and monocytes.C/EBPα in normal and malignant myelopoiesis.Identification and functional analysis of acute myeloid leukemia susceptibility associated single nucleotide polymorphisms at non-protein coding regions of RUNX1.The analysis of novel distal Cebpa enhancers and silencers using a transcriptional model reveals the complex regulatory logic of hematopoietic lineage specification.Expression of CEBPA is reduced in RUNX1-mutated acute myeloid leukemia.Response: the role of RUNX1 isoforms in hematopoietic commitment of human pluripotent stem cells.KSRP specifies monocytic and granulocytic differentiation through regulating miR-129 biogenesis and RUNX1 expression.ZNF143 protein is an important regulator of the myeloid transcription factor C/EBPα.Evaluation of CCAAT/Enhancer Binding Protein (C/EBP) Alpha (CEBPA) and Runt-Related Transcription Factor 1 (RUNX1) Expression in Patients with De Novo Acute Myeloid Leukemia.Pin1-mediated prolyl isomerization of Runx1 affects PU.1 expression in pre-monocytes.NR4A1 and NR4A3 restrict HSC proliferation via reciprocal regulation of C/EBPα and inflammatory signaling.The Ontogeny of a Neutrophil: Mechanisms of Granulopoiesis and Homeostasis.RUNX1 and CBFβ Mutations and Activities of Their Wild-Type Alleles in AML.LincRNA-uc002yug.2 involves in alternative splicing of RUNX1 and serves as a predictor for esophageal cancer and prognosis.
P2860
Q27329605-B57F4A24-E155-49CD-BD82-D3B47270E134Q30252938-7BF7CC9A-91B5-4CB8-8068-3B2A38EB0873Q30300790-531BA3B2-80DE-4B8D-876F-255CF443F40FQ30855561-4378EF4F-3B2E-4A27-A2C3-382E225AB918Q34066703-A358B77B-91E8-4A98-A58B-E633673DD000Q35154153-E4AECB44-3AB8-4C54-842F-302263C6697FQ35566633-65641791-AA8C-43DD-AE76-95E3C9FCA141Q35579282-7842B194-2C58-44B1-BD39-B773BD1A8E9DQ35944184-F4AB50A2-19AC-4AD7-8612-601BF6EAC049Q36442414-0C1D3706-6AC9-4AA1-81B0-268E33C20E19Q37015672-19EF41E5-998C-41A2-85CE-936545041FAEQ37034398-D23A6238-C720-4A9B-86E3-5FE68E768E1EQ37153598-E2222647-D43A-4A07-A63C-B1D5DB3B0D88Q37361836-4AC14FE6-FD3B-46F1-9E07-3170A96C1AEFQ38076281-2335E051-E04E-4A5C-8F25-E2C95CF8EF50Q38284004-9028F418-518F-4F6D-AC71-F2F18D4D8E3CQ38370875-CE01F67C-D4F5-47E2-AFA3-8FDED2F77346Q38835022-EF76595E-A188-42D0-BC23-3D164D4813EBQ39945896-F1BCA289-21A4-4B2E-9933-62B52B5B4EC8Q42322576-C864DF73-A542-4D80-8664-B49A23DA1260Q42684214-6975892A-9214-4D30-8320-3EC1D8BDBE5FQ47097839-28E4889C-5205-4F42-88B3-A54C6AB036C7Q47814357-A21F63AD-D644-4326-9AA2-D731D81B3078Q47819086-85CF555B-C1A9-4C0D-9E2E-7D44BC1A70F1Q47979002-D748829B-819F-489A-A68A-BF0DD446E8F2Q49990556-15377133-E98F-4F61-A442-C858EE868C1BQ50048317-2CEFBEFB-CF2E-4514-9AA4-06F3458A0BFAQ51097615-7C33715D-3F03-42EC-9F30-B5CE0672D769Q51676483-E14209FA-C98A-4C9F-909D-7C65E222B978
P2860
Runx1 deletion or dominant inhibition reduces Cebpa transcription via conserved promoter and distal enhancer sites to favor monopoiesis over granulopoiesis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Runx1 deletion or dominant inh ...... nopoiesis over granulopoiesis.
@ast
Runx1 deletion or dominant inh ...... nopoiesis over granulopoiesis.
@en
type
label
Runx1 deletion or dominant inh ...... nopoiesis over granulopoiesis.
@ast
Runx1 deletion or dominant inh ...... nopoiesis over granulopoiesis.
@en
prefLabel
Runx1 deletion or dominant inh ...... nopoiesis over granulopoiesis.
@ast
Runx1 deletion or dominant inh ...... nopoiesis over granulopoiesis.
@en
P2093
P2860
P1433
P1476
Runx1 deletion or dominant inh ...... nopoiesis over granulopoiesis.
@en
P2093
Alan D Friedman
Nancy A Speck
P2860
P304
P356
10.1182/BLOOD-2011-12-397091
P407
P577
2012-03-26T00:00:00Z